Frontline treatment regimens for multiple myeloma
| . | ASCT-intent . | ||
|---|---|---|---|
| . | Denosumab (n = 465) . | Zoledronic acid (n = 465) . | All patients (N = 930) . |
| Triplet therapy | |||
| CVd | 159 (34.2) | 177 (38.1) | 336 (36.1) |
| VTd | 80 (17.2) | 70 (15.1) | 150 (16.1) |
| VRd | 80 (17.2) | 61 (13.1) | 141 (15.2) |
| CTd | 52 (11.2) | 53 (11.4) | 105 (11.3) |
| MPV | 12 (2.6) | 12 (2.6) | 24 (2.6) |
| Vincristine, Adriamycin (doxorubicin), dexamethasone (VAD) | 11 (2.4) | 10 (2.2) | 21 (2.3) |
| KRd | 6 (1.3) | 5 (1.1) | 11 (1.2) |
| dVd | 3 (0.6) | 5 (1.1) | 8 (0.9) |
| MPT | 1 (0.2) | 0 | 1 (0.1) |
| CRd | 1 (0.2) | 2 (0.4) | 3 (0.3) |
| Liposomal doxorubicin, vincristine, dexamethasone (VAD) | 0 | 1 (0.2) | 1 (0.1) |
| Doublet therapy | |||
| Vd | 55 (11.8) | 59 (12.7) | 114 (12.3) |
| Rd | 12 (2.6) | 17 (3.7) | 29 (3.1) |
| Td | 14 (3.0) | 24 (5.2) | 38 (4.1) |
| VT | 2 (0.4) | 2 (0.4) | 4 (0.4) |
| VP | 2 (0.4) | 2 (0.4) | 4 (0.4) |
| Vd2 | 1 (0.2) | 0 | 1 (0.1) |
| Pd | 0 | 1 (0.2) | 1 (0.1) |
| Single agent | 40 (8.6) | 46 (9.9) | 86 (9.2) |
| Other | 28 (6.0) | 22 (4.7) | 50 (5.4) |
| DCEP | 1 (0.2) | 1 (0.2) | 2 (0.2) |
| VTD-PACE | 1 (0.2) | 1 (0.2) | 2 (0.2) |
| C-VAd | 1 (0.2) | 1 (0.2) | 2 (0.2) |
| Not applicable | 1 (0.2) | 2 (0.4) | 3 (0.3) |
| . | ASCT-intent . | ||
|---|---|---|---|
| . | Denosumab (n = 465) . | Zoledronic acid (n = 465) . | All patients (N = 930) . |
| Triplet therapy | |||
| CVd | 159 (34.2) | 177 (38.1) | 336 (36.1) |
| VTd | 80 (17.2) | 70 (15.1) | 150 (16.1) |
| VRd | 80 (17.2) | 61 (13.1) | 141 (15.2) |
| CTd | 52 (11.2) | 53 (11.4) | 105 (11.3) |
| MPV | 12 (2.6) | 12 (2.6) | 24 (2.6) |
| Vincristine, Adriamycin (doxorubicin), dexamethasone (VAD) | 11 (2.4) | 10 (2.2) | 21 (2.3) |
| KRd | 6 (1.3) | 5 (1.1) | 11 (1.2) |
| dVd | 3 (0.6) | 5 (1.1) | 8 (0.9) |
| MPT | 1 (0.2) | 0 | 1 (0.1) |
| CRd | 1 (0.2) | 2 (0.4) | 3 (0.3) |
| Liposomal doxorubicin, vincristine, dexamethasone (VAD) | 0 | 1 (0.2) | 1 (0.1) |
| Doublet therapy | |||
| Vd | 55 (11.8) | 59 (12.7) | 114 (12.3) |
| Rd | 12 (2.6) | 17 (3.7) | 29 (3.1) |
| Td | 14 (3.0) | 24 (5.2) | 38 (4.1) |
| VT | 2 (0.4) | 2 (0.4) | 4 (0.4) |
| VP | 2 (0.4) | 2 (0.4) | 4 (0.4) |
| Vd2 | 1 (0.2) | 0 | 1 (0.1) |
| Pd | 0 | 1 (0.2) | 1 (0.1) |
| Single agent | 40 (8.6) | 46 (9.9) | 86 (9.2) |
| Other | 28 (6.0) | 22 (4.7) | 50 (5.4) |
| DCEP | 1 (0.2) | 1 (0.2) | 2 (0.2) |
| VTD-PACE | 1 (0.2) | 1 (0.2) | 2 (0.2) |
| C-VAd | 1 (0.2) | 1 (0.2) | 2 (0.2) |
| Not applicable | 1 (0.2) | 2 (0.4) | 3 (0.3) |
Data are n (%).
C-CVd, cyclophosphamide, vincristine, Adriamycin (doxorubicin), dexamethasone; CRd, cyclophosphamide, lenalidomide, dexamethasone; DCEP, dexamethasone, cyclophosphamide, etoposide, cisplatin; dVd, liposomal doxorubicin, bortezomib, dexamethasone; KRd, carfilzomib, lenalidomide, dexamethasone; MPT, melphalan, prednisone, thalidomide; MPV, melphalan, prednisone, bortezomib; Pd, pomalidomide, dexamethasone; VAD, vincristine, Adriamycin (doxorubicin), dexamethasone; Vd2, bortezomib, liposomal doxorubicin; VP, bortezomib, prednisone; VT, bortezomib, thalidomide; VTD-PACE, dexamethasone, thalidomide, cisplatin, Adriamycin (doxorubicin), cyclophosphamide, etoposide, bortezomib.